All In Biotech

Drug Trial Radar · NCT00409357

Dose Ranging Study of Alfuzosin in Patients With Lower Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia

A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose Ranging Study of SL77.0499-10 Once Daily Tablets in Patients With Lower Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia (BPH)

Last checked: Nov 20, 2026Latest source record: Oct 2, 2009 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 473 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

473

Actual

Start

Nov 2004

Primary completion

Aug 2005

Study completion Aug 2005

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Dec 8, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
Male only, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective is to assess the dose-response relationship of SL77.0499 10 (alfuzosin hydrochloride) 5 mg, 10 mg, 15 mg, and placebo once daily during a 12-week oral administration period for the efficacy in patients with lower urinary tract symptoms (LUTS) related to BPH. Secondary objectives are to assess the efficacy of each dose of alfuzosin as compared with placebo and to assess the safety of each dose of alfuzosin.

Conditions

  • Benign Prostatic Hyperplasia

Interventions

  • SL77.0499-10 (alfuzosin hydrochloride)Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The primary efficacy assessment is the change from baseline in International Prostate Symptom Score (IPSS) total score at the end-of-study (EOS) visit.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sanofi-Aventis

    Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.